Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.32 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163341 | 0.74 | CSNK2A1 (0.35) | CSNK2A1CSNK2A2CSNK2BCSNK2A3IDO1 | |
| SCHEMBL29249597 | 0.71 | CSNK2A1 (0.31) | CSNK2A1 | |
| SCHEMBL11922643 | 0.71 | HTT (0.42) | CSNK2A1 | |
| SCHEMBL19635567 | 0.71 | CSNK2A1 (0.33) | CSNK2A1CSNK2A2CSNK2BCSNK2A3IDO1 | |
| SCHEMBL19615636 | 0.71 | IDO1 (0.37) | CSNK2A1CSNK2A2CSNK2BCSNK2A3IDO1 | |
| SCHEMBL17853102 | 0.68 | NOTUM (0.32) | — | |
| SCHEMBL19635231 | 0.68 | CSNK2A1 (0.31) | CSNK2A1IDO1 | |
| SCHEMBL15273689 | 0.68 | CSNK2A1 (0.32) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL19635866 | 0.68 | IDO1 (0.33) | CSNK2A1CSNK2A2CSNK2BCSNK2A3IDO1 | |
| SCHEMBL19616038 | 0.68 | POLB (0.39) | CSNK2A1CSNK2A2CSNK2BCSNK2A3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492358-B1 | Macrocyclic indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| CN-109715632-B | Macrocyclic indole derivatives | 拜尔公开股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492358-B1 | Macrocyclic indole derivatives | CCND2, CCNT2, IDO1 | CSNK2A1 856/4885CSNK2A2 986/4885CSNK2B 1077/4885 |
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | CSNK2A1 980/4885CSNK2A2 1074/4885CSNK2B 1154/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | CSNK2A1 841/4885CSNK2A2 995/4885CSNK2B 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.